The Defense Health Agency awarded a $718,829 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System Incorporated, to study "Ergothioneine and Its Analog Ovothiol A Target Traumatic Brain Injury and Comorbid Alcohol Use Disorder." The grant period runs from September 1, 2024 to August 31, 2027. The funding supports innovative biomedical research focused on developing treatments for traumatic brain injury and comorbid alcohol use disorder, which are health challenges relevant to military personnel. Brigham & Women's Hospital, a leading academic medical center, will leverage its expertise in areas like neurology and clinical research to conduct this study aimed at advancing scientific knowledge and improving patient outcomes.
Generated 3/25/25, 3:13 AM